June CH, O’Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359:1361–5.

Article  CAS  PubMed  Google Scholar 

US Food and Drug Administration: KYMRIAH (tisagenlecleucel). 2024. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/kymriah-tisagenlecleucel. Accessed 9 Oct 2024.

US Food and Drug Administration: YESCARTA (axicabtagene ciloleucel). 2024. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/yescarta-axicabtagene-ciloleucel. Accessed 9 Oct 2024.

US Food and Drug Administration: TECARTUS (brexucabtagene autoleucel). 2024. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/tecartus-brexucabtagene-autoleucel. Accessed 9 Oct 2024.

US Food and Drug Administration: BREYANZI (lisocabtagene maraleucel). 2024. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/breyanzi-lisocabtagene-maraleucel. Accessed 9 Oct 2024.

US Food and Drug Administration: ABECMA (idecabtagene vicleucel). 2024. https://www.fda.gov/vaccines-blood-biologics/abecma-idecabtagene-vicleucel. Accessed 9 Oct 2024.

US Food and Drug Administration: CARVYKTI (ciltacabtagene autoleucel). 2024. https://www.fda.gov/vaccines-blood-biologics/carvykti. Accessed 9 Oct 2024.

Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L. ‘Off-the-shelf’ allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020;19:185–99.

Article  CAS  PubMed  Google Scholar 

Amini L, Silbert SK, Maude SL, Nastoupil LJ, Ramos CA, Brentjens RJ, et al. Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion. Nat Rev Clin Oncol. 2022;19:342–55.

Article  PubMed  Google Scholar 

Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol. 2022;22:85–96.

Article  CAS  PubMed  Google Scholar 

Zhang H-X, Zhang Y, Yin H. Genome Editing with mRNA Encoding ZFN, TALEN, and Cas9. Mol Ther. 2019;27:735–46.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Doudna JA. The promise and challenge of therapeutic genome editing. Nature. 2020;578:229–36.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pickar-Oliver A, Gersbach CA. The next generation of CRISPR-Cas technologies and applications. Nat Rev Mol Cell Biol. 2019;20:490–507.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang JY, Doudna JA. CRISPR technology: A decade of genome editing is only the beginning. Science. 2023;379:eadd8643.

Article  CAS  PubMed  Google Scholar 

Wang D, Zhang F, Gao G. CRISPR-Based Therapeutic Genome Editing: Strategies and In Vivo Delivery by AAV Vectors. Cell. 2020;181:136–50.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yeh CD, Richardson CD, Corn JE. Advances in genome editing through control of DNA repair pathways. Nat Cell Biol. 2019;21:1468–78.

Article  CAS  PubMed  Google Scholar 

Makarova KS, Wolf YI, Iranzo J, Shmakov SA, Alkhnbashi OS, Brouns SJJ, et al. Evolutionary classification of CRISPR–Cas systems: a burst of class 2 and derived variants. Nat Rev Microbiol. 2020;18:67–83.

Article  CAS  PubMed  Google Scholar 

Liu X, Zhang Y, Cheng C, Cheng AW, Zhang X, Li N, et al. CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells. Cell Res. 2017;27:154–7.

Article  PubMed  Google Scholar 

Zetsche B, Gootenberg JS, Abudayyeh OO, Slaymaker IM, Makarova KS, Essletzbichler P, et al. Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system. Cell. 2015;163:759–71.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hille F, Richter H, Wong SP, Bratovič M, Ressel S, Charpentier E. The Biology of CRISPR-Cas: Backward and Forward. Cell. 2018;172:1239–59.

Article  CAS  PubMed  Google Scholar 

Strohkendl I, Saifuddin FA, Rybarski JR, Finkelstein IJ, Russell R. Kinetic Basis for DNA Target Specificity of CRISPR-Cas12a. Mol Cell. 2018;71:816–24.e3

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kleinstiver BP, Tsai SQ, Prew MS, Nguyen NT, Welch MM, Lopez JM, et al. Genome-wide specificities of CRISPR-Cas Cpf1 nucleases in human cells. Nat Biotechnol. 2016;34:869–74.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Singh J, Liu KG, Allen A, Jiang W, Qin PZ. A DNA unwinding equilibrium serves as a checkpoint for CRISPR-Cas12a target discrimination. Nucleic Acids Res. 2023;51:8730–43.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim D, Kim J, Hur JK, Been KW, Yoon S, Kim J-S. Genome-wide analysis reveals specificities of Cpf1 endonucleases in human cells. Nat Biotechnol. 2016;34:863–8.

Article  CAS  PubMed  Google Scholar 

Swarts DC, Jinek M. Cas9 versus Cas12a/Cpf1: Structure-function comparisons and implications for genome editing. Wiley Interdiscip Rev RNA. 2018;9:e1481.

Article  PubMed  Google Scholar 

Xun G, Zhu Z, Singh N, Lu J, Jain PK, Zhao H. Harnessing noncanonical crRNA for highly efficient genome editing. Nat Commun. 2024;15:1–13.

Article  Google Scholar 

Siegler EL, Simone BW, Sakemura R, Tapper EE, Horvei P, Cox MJ, et al. Efficient Gene Editing of CART Cells with CRISPR-Cas12a for Enhanced Antitumor Efficacy. Blood. 2020;136:6–7.

Article  Google Scholar 

Zetsche B, Heidenreich M, Mohanraju P, Fedorova I, Kneppers J, DeGennaro EM, et al. Multiplex gene editing by CRISPR-Cpf1 using a single crRNA array. Nat Biotechnol. 2017;35:31–4.

Article  CAS  PubMed  Google Scholar 

Dai X, Park JJ, Du Y, Kim HR, Wang G, Errami Y, et al. One-step generation of modular CAR-T cells with AAV–Cpf1. Nat Methods. 2019;16:247–54.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li T, Zhu L, Xiao B, Gong Z, Liao Q, Guo J. CRISPR-Cpf1-mediated genome editing and gene regulation in human cells. Biotechnol Adv. 2019;37:21–27.

Article  CAS  PubMed  Google Scholar 

Paul B, Montoya G. CRISPR-Cas12a: Functional overview and applications. Biomed J. 2020;43:8–17.

Article  PubMed  PubMed Central  Google Scholar 

Dai X, Park JJ, Du Y, Kim HR, Wang G, Errami Y, et al. One-step generation of modular CAR-T cells with AAV-Cpf1. Nat Methods. 2019;16:247–54.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Qi LS, Larson MH, Gilbert LA, Doudna JA, Weissman JS, Arkin AP, et al. Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression. Cell. 2013;152:1173–83.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu G, Lin Q, Jin S, Gao C. The CRISPR-Cas toolbox and gene editing technologies. Mol Cell. 2022;82:333–47.

Article  CAS  PubMed  Google Scholar 

Nakamura M, Gao Y, Dominguez AA, Qi LS. CRISPR technologies for precise epigenome editing. Nat Cell Biol. 2021;23:11–22.

Article  CAS  PubMed  Google Scholar